Chronic phenmetrazine treatment promotes D2 dopaminergic and α2-adrenergic receptor desensitization and alters phosphorylation of signaling proteins and local cerebral glucose metabolism in the rat brain

• Published in: Brain research 2021-06, Vol.1761, p.147387-147387, Article 147387
• Main Authors: Keegan, Bradley M., Dreitzler, Annie L., Sexton, Tammy, Beveridge, Thomas J.R., Smith, Hilary R., Miller, Mack D., Blough, Bruce E., Porrino, Linda J., Childers, Steven R., Howlett, Allyn C.
• Format: Article
• Language: English
• Subjects: 2-[14C]-deoxyglucose; Cyclic AMP (cAMP); Dopamine transporter (DAT); G-protein-coupled receptor (GPCR); G-proteins; Local cerebral glucose utilization (LCGU)
• ISSN: 0006-8993; 1872-6240
• DOI: 10.1016/j.brainres.2021.147387

[Display omitted] •Phenmetrazine (PHEN) is a putative treatment for cocaine addiction.•PHEN acutely stimulated glucose utilization in basal ganglia and motor brain regions.•Chronic PHEN decreased D2 and α2-adrenergic receptor-mediated G-protein activation.•PHEN altered the phosphorylation states of ERK1/2, GSK3β, and DARPP-32.•PHEN promoted desensitization and changes in cell signaling and brain metabolism. Phenmetrazine (PHEN) is a putative treatment for cocaine and psychostimulant recidivism; however, neurochemical changes underlying its activity have not been fully elucidated. We sought to characterize brain homeostatic adaptations to chronic PHEN, specifically on functional brain activity (local cerebral glucose utilization), G-Protein Coupled Receptor-stimulated G-protein activation, and phosphorylation of ERK1/2Thr202/Tyr204, GSK3βTyr216, and DARPP-32Thr34. Male Sprague-Dawley rats were implanted with sub-cutaneous minipumps delivering either saline (vehicle), acute (2-day) or chronic (14-day) low dose (25 mg/kg/day) or high dose (50 mg/kg/day) PHEN. Acute administration of high dose PHEN increased local cerebral glucose utilization measured by 2-[14C]-deoxyglucose uptake in basal ganglia and motor-related regions of the rat brain. However, chronically treated animals developed tolerance to these effects. To identify the neurochemical changes associated with PHEN’s activity, we performed [35S]GTPγS binding assays on unfixed and immunohistochemistry on fixed coronal brain sections. Chronic PHEN treatment dose-dependently attenuated D2 dopamine and α2-adrenergic, but not 5-HT1A, receptor-mediated G-protein activation. Two distinct patterns of effects on pERK1/2 and pDARPP-32 were observed: 1) chronic low dose PHEN decreased pERK1/2, and also significantly increased pDARPP-32 levels in some regions; 2) acute and chronic PHEN increased pERK1/2, but chronic high dose PHEN treatment tended to decrease pDARPP-32. Chronic low dose, but not high dose, PHEN significantly reduced pGSK3β levels in several regions. Our study provides definitive evidence that extended length PHEN dosage schedules elicit distinct modes of neuronal acclimatization in cellular signaling. These pharmacodynamic modifications should be considered in drug development for chronic use.